Healthcare -
Biotechnology - NASDAQ - US
$ 1.07
0 %
$ 64.8 M
Market Cap
-0.55
P/E
1. INTRINSIC VALUE
Balance Sheet
Acumen Pharmaceuticals, Inc.
| Current Assets | 178 M |
| Cash & Short-Term Investments | 172 M |
| Receivables | 398 K |
| Other Current Assets | 6.35 M |
| Non-Current Assets | 60.7 M |
| Long-Term Investments | 60 M |
| PP&E | 339 K |
| Other Non-Current Assets | 379 K |
| Current Liabilities | 27.6 M |
| Accounts Payable | 5.65 M |
| Short-Term Debt | 266 K |
| Other Current Liabilities | 21.7 M |
| Non-Current Liabilities | 29.6 M |
| Long-Term Debt | 29.6 M |
| Other Non-Current Liabilities | 0 |
EFFICIENCY
Earnings Waterfall
Acumen Pharmaceuticals, Inc.
| Revenue | 0 |
| Cost Of Revenue | 0 |
| Gross Profit | 0 |
| Operating Expenses | 114 M |
| Operating Income | -114 M |
| Other Expenses | -11.7 M |
| Net Income | -102 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Acumen Pharmaceuticals, Inc.
| Net Income | -102 M |
| Depreciation & Amortization | 178 K |
| Capital Expenditures | -16 K |
| Stock-Based Compensation | 9.64 M |
| Change in Working Capital | 11.7 M |
| Others | 2.03 M |
| Free Cash Flow | -86.2 M |
Wall Street Analysts Price Targets
Acumen Pharmaceuticals, Inc.
Wall Street analysts predict an average 1-year price target for ABOS of $7 , with forecasts ranging from
a
low of
$7 to a high of $7 .
ABOS Lowest Price Target
Wall Street Target
7 USD
554.21%
ABOS Average Price Target
Wall Street Target
7 USD
554.21%
ABOS Highest Price Target
Wall Street Target
7 USD
554.21%
4. DIVIDEND
ANALYSIS
ABOS does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Acumen Pharmaceuticals, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
259 K USD 5
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Acumen Pharmaceuticals, Inc. (ABOS) Q1 2025 Earnings Call Transcript
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS ) Q1 2025 Earnings Conference Call May 13, 2025 8:00 AM ET Company Participants Alex Braun - Head, Investor Relations Dan O'Connell - Chief Executive Officer Matt Zuga - Chief Financial Officer and CBO Dr. Jim Doherty - President and CDO Dr. Eric Siemers - Chief Medical Officer Conference Call Participants Sarah Medeiros - Cantor Fitzgerald Tom Shrader - BTIG Ting Liu - UBS Operator Good day and thank you for standing by. Welcome to the Acumen Pharmaceuticals Q1 2025 Conference Call and Webcast.
seekingalpha.com
- 1 month ago
Acumen Pharmaceuticals to Participate in the Bank of America Healthcare Conference
NEWTON, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate in in a fireside chat at the Bank of American Healthcare Conference on Wednesday, May 14, 2025, at 8:15 a.m. PT/11:15 a.m. ET.
globenewswire.com
- 1 month ago
Acumen Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025
NEWTON, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, today announced that the Company will report first quarter 2025 financial results on Tuesday, May 13, 2025. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update.
globenewswire.com
- 1 month ago
Acumen Pharmaceuticals Showcases pTau217 Trial Screening Progress in Phase 2 ALTITUDE-AD Trial and Preclinical Research Methods at AD/PD 2025 and AAN Annual Meeting
Biomarker results from Phase 1 INTERCEPT-AD trial of sabirnetug in patients with early Alzheimer's disease recently published in The Journal of Prevention of Alzheimer's Disease Biomarker results from Phase 1 INTERCEPT-AD trial of sabirnetug in patients with early Alzheimer's disease recently published in The Journal of Prevention of Alzheimer's Disease
globenewswire.com
- 2 months ago
Acumen Pharmaceuticals, Inc. (ABOS) Q4 2024 Earnings Call Transcript
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS ) Q4 2024 Earnings Conference Call March 27, 2025 8:00 AM ET Company Participants Alex Braun - Head, Investor Relations Dan O'Connell - Chief Executive Officer Matt Zuga - Chief Financial Officer and Chief Business Officer Jim Doherty - President and Chief Development Officer Eric Siemers - Chief Medical Officer Conference Call Participants Jason Zemansky - Bank of America Pete Stavropoulos - Cantor Fitzgerald Ting Liu - UBS Tom Shrader - BTIG Ananda Ghosh - H. C. Wainwright & Company Operator Good day and welcome to Acumen Pharma Fiscal Year 2024 Conference Call and Webcast.
seekingalpha.com
- 2 months ago
Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2024 Financial Results on March 27, 2025
NEWTON, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, today announced that the Company will report fourth quarter and year-end 2024 financial results on Thursday, March 27, 2025. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update.
globenewswire.com
- 2 months ago
Acumen Pharmaceuticals CEO Discusses Novel Targeted Therapies for Alzheimer's
NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Today's Marketplace (TMP) is proud to announce a featured interview with Acumen Pharmaceuticals (NASDAQ: ABOS) CEO Daniel O ' Connell and Jessica Clark, DNP, RN, Dean of the College of Nursing at Creighton University. The pair joined Today's Marketplace host Elizabeth Hart to discuss Alzheimer's Disease.
globenewswire.com
- 2 months ago
Acumen Pharmaceuticals to Present During International Conference on Alzheimer's and Parkinson's Diseases 2025 and American Academy of Neurology Annual Meeting
Oral presentations will highlight the implementation of a validated research-use plasma pTau217 assay in the participant screening process for the Phase 2 ALTITUDE-AD study of sabirnetug Oral presentations will highlight the implementation of a validated research-use plasma pTau217 assay in the participant screening process for the Phase 2 ALTITUDE-AD study of sabirnetug
globenewswire.com
- 3 months ago
Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences
NEWTON, Mass., March 10, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate in webcast fireside chats at two upcoming investor conferences:
globenewswire.com
- 3 months ago
Acumen Pharmaceuticals to Participate in the 7th Annual Evercore ISI HealthCONx Conference
NEWTON, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference on Tuesday, Dec. 3, 2024, at 3:00 p.m. ET.
globenewswire.com
- 6 months ago
Acumen Pharmaceuticals, Inc. (ABOS) Q3 2024 Earnings Call Transcript
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS ) Q3 2024 Results Conference Call November 12, 2024 8:00 AM ET Company Participants Alex Braun - Head of Investor Relations Dan O'Connell - Chief Executive Officer Matt Zuga - Chief Financial Officer, Chief Business Officer Dr. Jim Doherty - President, Chief Development Officer Dr. Eric Siemers - Chief Medical Officer. Conference Call Participants Mark Hitrik - Stifel Tom Shrader - BTIG Cameron Bozdog - BofA Securities Samantha Schaeffer - Cantor Fitzgerald Operator Hello, and welcome to Acumen Pharmaceuticals Q3 2024 Conference Call and Webcast.
seekingalpha.com
- 7 months ago
Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference
NEWTON, Mass., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate in a fireside chat at the Stifel Healthcare Conference on Monday, Nov. 18, 2024, at 11:30 a.m. ET.
globenewswire.com
- 7 months ago
8. Profile
Summary
Acumen Pharmaceuticals, Inc. ABOS
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 64.8 M
Dividend Yield
0.00%
Description
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
Contact
427 Park Street, Newton, VA, 22902
https://acumenpharm.com
IPO
Date
July 1, 2021
Employees
61
Officers
Ms. Alex Braun M.B.A.
Vice President & Head of Investor Relations
Ms. Kelly Carranza
Vice President, Finance & Accounting and Corporate Controller
Dr. Caleb E. Finch Ph.D.
Co-Founder
Mr. Matt Zuga
Chief Financial Officer & Chief Business Officer
Mr. Daniel J. O'Connell M.B.A.
Chief Executive Officer & Director
Mr. Derek M. Meisner Esq., J.D.
Chief Legal Officer & Corporate Secretary
Dr. William L. Klein Ph.D.
Co-Founder
Dr. James Doherty Ph.D.
President & Chief Development Officer
Dr. Grant A. Krafft Ph.D.
Co-Founder
Mr. Russell Barton M.S.
Chief Operating Officer